Serum levels of cytokines after bone marrow transplantation: Increased IL-8 levels during severe veno-occlusive disease of the liver

European Journal of Haematology

Volumn 59, Issue 4, 1997, Pages 254-262

  Remberger, M ^a   Ringden O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

aGVHD; Bacteraemia; Cytokines; IL 8; VOD

Indexed keywords

CYTOKINE; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CELL TYPE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER VEIN OBSTRUCTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0030847472     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb00985.x     Document Type: Article

References (55)

1. THOMAS E, STORB R, CLIFT R, et al. Bone-marrow transplantation I and II. N Engl J Med 1975: 292: 832-902.
2. THOMAS E, LOCHTE JHL, LU W, FERREBEE J. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957: 257: 491-496.
3. BAGLIN T. Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant 1994: 13: 1-4.
4. SHULMAN H, HINTERBERGER W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992: 10: 197-214.
5. BRODSKY R, TOPOLSKY D, CRILLEY P, BULOVA S, BRODSKY I. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulphan/cyclophosphamide preparative regimen. Am J Clin Oncol 1990: 13: 221-225.
6. BLOSTEIN M, PALTIEL O, THIBAULT A, RYBKA W. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant. 1992: 10: 439-443.
7. JONES R, LEE K, BESCHORNER W, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987: 44: 778-787.
8. MCDONALD G, SHARMA P, MATTHEWS D, et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984: 4: 116-122.
9. CARRERAS E, GRANENA A, ROZMAN C. Hepatic veno-occlusive disease after bone marrow transplantation. Blood Rev 1993: 7: 43-51.
10. MCDONALD G, HINDS M, FISHER L, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993: 118: 255-267.
11. ROLLINS B. Hepatic veno-occlusive disease. Am J Med 1986: 81: 297-306.
12. HOLLER E, KOLB H, MOLLER A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990: 75: 1011-1016.
13. VAN HINSBERGH V, KOOISTRA T, VAN DEN BERG E. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988: 72: 1467-1473.
14. REMBERGER M, RINGDÉN O. Increased levels of soluble interleukin-2 receptors in veno-occlusive disease of the liver after allogenic bone marrow transplantation. Transplantation 1995: 60: 1293-1299.
15. TAUB D, OPPENHEIM J. Review of the Chemokine Meeting, the Third International Symposium of the Chemotactic Cytokines. Cytokine 1993: 5: 175-179.
16. FERRARA J, DEEG H. Graft-versus-host disease. N Engl J Med 1991: 324: 667-674.
17. KERNAN N, COLLINS N, JULIANO L, CARTAGENA T, DUPONT B, O'REILLY R. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986: 68: 770-773.
18. RINGDÉN O, PIHLSTEDT P, MARKLING L, et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate: a randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991: 7: 221-226.
19. COHEN J. Cytokines as mediators of graft-versus-host disease. Bone Marrow Transplant 1988: 3: 193-197.
20. ANTIN J, FERRARA J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992: 80: 2964-2968.
21. JADUS M, WEPSIC H. The role of cytokines in graft-versus-host reaction and disease. Bone Marrow Transplant 1992: 10: 1-14.
22. HOLLER E, KOLB H, HINTERMEIER-KNABE R, et al. The role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogenic bone marrow transplantation. Transplant Proc 1993: 25: 1234-1236.
23. SYMINGTON F, SYMINGTON B, LIU P, VIGUET H, SANTHANAM U, SEHGAL P. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992: 54: 457-462.
24. PIGUET P, GRAU G, ALLET B, VASSALLI P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987: 166: 1280-1289.
25. REMBERGER M, RINGDÉN O, MARKLING L. TNFa levels are increased during BMT conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995: 15: 99-104.
26. BUNGES D, HARDT C, RÖLLINGHOFF M, WAGNER H. Cyclosporin A mediates immunosuppression of primary cytotoxic T-cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981: 11: 657-661.
27. HERVE P, BORDIGONI P, CAHN JY, et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation. Transplant Proc 1991: 23: 1692-1694.
28. HERVÉ P, FLESCH M, TIBERGHIEN P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992: 79: 3362-3368.
29. ANASETTI C, HANSEN JA, WALDMANN TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994: 84: 1320-1327.
30. BELANGER C, ESPEROU BH, BORDIGONI P, et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 1993: 11: 293-297.
31. HOLLER E, KOLB H, MITTERMULLER J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 1995: 86: 890-899.
32. RINGDÉN O, HEIMDAL A, LÖNNQVIST B, MALMBORG A, WILCZEK H. Decreased incidence of viridans streptococcal septicaemia in allogenic bone marrow transplants after the introduction of acyclovir. Lancet 1984: i: 744.
33. WATSON J. Problems of infection after bone marrow transplantation. J Clin Pathol 1983: 36: 683.
34. WINSTON D, GALE R, MEYER D, YOUNG L, GROUP AT UBMT. Infectious complications of human bone marrow transplantation. Medicine 1979: 58: 1-31.
35. MEYERS J, THOMAS E. Infection complicating bone marrow transplantation. In: RUBIN RH, YOUNG LS, eds. Clinical approach to infection in the compromised host. New York: Plenum Publishing Corp., 1988: 525-556.
36. MACINTYRE S, KUSHNER I, SAMOLS D. Secretion of C-reactive protein becomes more efficient during the course of the acute phase response. J Biol Chem 1985: 260: 4169-4173.
37. CASTELL J, GOMEZ-LECHON M, DAVID M, FABRA R, TRULLEQUE R, HEINRICH P. Acute phase response of human hepatocytes: regulation of acute phase protein synthesis by interleukin 6. Hepatology 1990: 12: 1179-1186.
38. WALKER S, ROGERS T, RICHES P, WHITE S, HOBBS J. Value of C-reactive protein measurement in the management of bone marrow transplant recipients. J Clin Path 1984: 37: 1018.
39. SCHWAIGHOFER H, HEROLD M, SCHWARZ T, et al. Serum levels of interleukin 6 interleukin 8 and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994: 58: 430-436.
40. TRACEY K, VLASSARA H, CERAMI A. Cachectin/tumor necrosis factor. Lancet 1989: i: 1122.
41. WAAGE A, HALSTENSEN A, ESPEVIK T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987: i: 355.
42. BEUTLER G, MILSARK I, CERAMI A. Passive immunization against tumor necrosis factor protects mice from the lethal effect of endotoxin. Science 1985: 229: 869.
43. WAAGE A, BRANDTZAEG P, HALSTENSEN A, KIERULF P, ESPEVIK T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989: 169: 333-338.
44. RINGDÉN O, RUUTU T, REMBERGER M, et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogenic marrow transplant recipient with leukemia. Blood 1994: 83: 2723-2730.
45. RINGDÉN O, BÄCKMAN L, SUNDBERG B, et al. Allogenic bone marrow transplantation for leukemia; factors of importance for long-term survival and relapse. Bone Marrow Transplant 1988: 3: 281-290.
46. RINGDÉN O, KLAESSON S, SUNDBERG B, LJUNGMAN P, LÖNNQVIST B, PERSSON U. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporine, as compared to monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992: 9: 19-25.
47. STORB R, DEEG HJ, WHITEHEAD, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729-735.
48. ASCHAN J, RINGDÉN O, ANDSTRÖM E, LJUNGMAN P, LÖNNQVIST B, REMBERGER M. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transplant 1994: 14: 79-87.
49. ATTAL M, HUGUET F, HERVE R, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992: 79: 2834-2840.
50. RUBIN L, KURMAN C, FRITZ M, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985: 135: 3172-3177.
51. BEARMAN S, SHUHART M, HINDS M, MCDONALD G. Recombinant human tissue plasminogen activator (tPA) for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation. Blood 1992: 80: 2458-2462.
52. MCDONALD G, SHARMA P, MATTHEWS D, SHULMAN H, THOMAS E. The clinical course of 53 patients with veno-cclusive disease of the liver after bone marrow transplantation. Transplant 1985: 39: 603-608.
53. FIORENTINO D, ZLOTNIK A, MOSMANN T, HOWARD M, O'GARRA A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991: 147: 3815-3822.
54. BACCHETTA R, BIGLER M, TOURINE J, et al. High levels of IL-10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoetic stem cells. J Exp Med 1994: 179: 493.
55. ROWBOTTOM A, RICHES P, DOWNIE C, HOBBS J. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 1993: 12: 635-641.